Stifel lowered the firm’s price target on Bolt Biotherapeutics (BOLT) to $1.25 from $1.50 and keeps a Hold rating on the shares. Completion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback